Clinical trials: OHT - Ocular Hypertension
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle…
- Trial name
- Firecrest (NCT07354516)
- Testing
- QLS-111-FDC, Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qlaris Bio, Inc.
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.